secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2025-09-10T23:59:59+00:00
Accession:  0001438533-25-000049
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA says no advisory committee needed for FILSPARI sNDA in FSGS; PDUFA Jan 13, 2026
--------------------------------------------------------------------------------

- FDA informed Travere that an advisory committee is no longer needed for the FILSPARI (sparsentan) sNDA for FSGS.
- The sNDA remains under review with a PDUFA target action date of January 13, 2026.
- If approved, FILSPARI would be the first medication indicated for FSGS, a rare kidney disorder.
- sNDA is supported by Phase 3 DUPLEX and Phase 2 DUET studies showing superior proteinuria reduction vs. irbesartan.
- FILSPARI is already fully approved for IgA nephropathy in the US and EU.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000049/0001438533-25-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000049/tvtx-20250910.htm
  HTML page:      https://secwatch.observer/filing/0001438533-25-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer